Atopic dermatitis (Ad) is a widespread inflammatory skin condition affecting individuals of all
age groups. recent research has identified Ad in older patients as a distinct clinical entity (1) …

Atopic dermatitis (AD) is a chronic, inflammatory, and pruritic skin disease. Recently,
upadacitinib, a selective JAK-1 inhibitor, has been incorporated for AD treatment. Real …

Atopic dermatitis (Ad) is a chronic debilitating inflammatory skin disease of fluctuating
course, with a lifetime prevalence of up to 20%(1). Although Ad still has an unmet need for …

Dear Editor, Upadacitinib is an oral Janus kinase (JAK)-1 inhibitor approved by the
European Medicine Agency for the management of moderate to severe atopic dermatitis …

Background: Limited real-world data are available on upadacitinib drug survival in patients
with atopic dermatitis (AD). Objectives: To investigate upadacitinib drug survival, and the …

Background Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease with
different clinical phenotypes based on factors such as age, race, comorbidities, and clinical …

Introduction The treatment of severe atopic dermatitis (AD) includes cyclosporine and
recently approved biologics and small molecules. Among these, upadacitinib is a selective …

Introduction Atopic dermatitis is one of the most prevalent chronic skin diseases. Topical
therapies continue to be the mainstay of treatment but are limited by noncompliance and …

Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for
moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years …

Upadacitinib is a selective Janus kinase inhibitor approved for the treatment of severe atopic
dermatitis (AD). This systematic review aims to summarize the most recent data in terms of …